Breaking News, Collaborations & Alliances

Bio-Thera Solutions & Intas Pharmaceuticals Expand Partnership

The partnership now includes an exclusive commercialization and license agreement in Canada for BAT2506.

By: Rachel Klemovitch

Assistant Editor

Bio-Thera Solutions, a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, expanded its partnership with Intas Pharmaceuticals for BAT2506, a proposed golimumab biosimilar, through an exclusive commercialization and license agreement for Canada. BAT2506 is a proposed golimumab biosimilar developed by Bio-Thera. Golimumab is a human IgG1 monoclonal antibody that targets tumor necrosis factor alpha, a pro-inflammatory molecule.  The ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters